TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

TIVORBEX

INDOMETHACIN
Approved 2014-02-24
1
Indication
--
Phase 3 Trials
12
Years on Market

Details

Status
Discontinued
First Approved
2014-02-24
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: INDOMETHACIN

TIVORBEX Approval History

Loading approval history...

What TIVORBEX Treats

1 FDA approvals

Originally approved for its first indication in 2014 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TIVORBEX FDA Label Details

Pro

TIVORBEX Patents & Exclusivity

Latest Patent: Apr 2030

Patents (12 active)

US9089471 Expires Apr 23, 2030
US8734847 Expires Apr 23, 2030
US8992982 Expires Apr 23, 2030
+ 2 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.